Publications by authors named "G K SeGall"
Article Synopsis
- The study focused on understanding the patterns of RET fusion-positive non-small cell lung cancer (NSCLC) among Chinese patients, specifically looking at demographics, clinical features, and treatment outcomes.
- It analyzed real-world data from 121 patients between January 2016 and November 2021, noting high biomarker testing rates and common gene fusion partners like KIF5B and CCDC6.
- Results showed that advanced-stage patients typically received platinum-based chemotherapy, with a median overall survival of 30.7 months, while early-stage patients had an impressive 86% event-free survival rate at two years.
Objective: This study aimed to describe real-world patient and physician characteristics, rearranged during transfection (RET) mutation testing and results, treatment patterns, and patient-reported outcomes (PROs) in advanced or metastatic medullary thyroid cancer (aMTC) across five populous European countries.
Methods: Cross-sectional physician and patient surveys were used to collect quantitative and qualitative data in France, Germany, Italy, Spain, and the UK from July to December 2020, prior to the introduction of selective RET inhibitors in Europe. Physicians completed patient record forms and a survey about their specialty and practice site.
To provide a real-world snapshot of the clinical profile, management, and patient-reported outcomes (PRO) for advanced medullary and papillary thyroid cancer prior to the availability of rearranged during transfection (RET) inhibitors in Japan. Physicians completed patient-record forms for eligible patients seen during routine clinical practice. Physicians were also surveyed about their routine practice and patients were asked to provide PRO data.
View Article and Find Full Text PDF